Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)
This is a Phase II, open-label, multicenter, single-arm, exploratory "proof of concept" study. Diflomotecan (7 mg fixed dose) will be administered as a 20-minute IV infusion once every 3 weeks in patients with sensitive small cell lung cancer (SCLC) with progressive disease after first-line treatment with a platinum-based regimen.
Small Cell Lung Cancer
DRUG: Diflomotecan (BN80915)
Overall objective response rate (tumour assessments should be performed every 6 weeks)
Time to tumour progression|Time to treatment failure|Duration of overall response|Overall complete response, partial response and stable disease|Time to response|Six month and one year survival rates|Median survival|Best overall response|Overall objective response rate
This is a Phase II, open-label, multicenter, single-arm, exploratory "proof of concept" study. Diflomotecan (7 mg fixed dose) will be administered as a 20-minute IV infusion once every 3 weeks in patients with sensitive small cell lung cancer (SCLC) with progressive disease after first-line treatment with a platinum-based regimen.